February 12, 1995
Joseph L. Seibold has been promoted to senior vice president and manager of the Southwest region for O'Brien-Kreitzberg & Associates Inc., the nation's largest pure construction management firm. Seibold, who will work out of the firm's Encino office, was formerly vice president. He will oversee the region which includes Southern California, southern Nevada and Arizona.
October 7, 2000
Boeing Co. said it has completed a $3.75-billion purchase of Hughes Electronics Corp.'s satellite-making business, boosting Boeing's space-based revenue to nearly $10 billion a year. Boeing, already the world's biggest plane maker, renamed the 9,000-employee, El Segundo-based Hughes unit Boeing Satellite Systems and said it would help the Seattle-based company's space and communications division grow faster than its core commercial airplane business and its military unit.
September 6, 2004 |
In an advance that could lead to lighter spacecraft and smarter cars, researchers have developed a technique for producing a high-quality computer chip that is much more resistant to extreme conditions than the silicon found in most of today's electronics.
February 16, 2001 |
Watson Pharmaceuticals Inc. said Thursday that it had a fourth-quarter loss because of costs associated with recent acquisitions. The Corona-based pharmaceuticals maker lost $1.9 million, or 2 cents a share, contrasted with net income of $73.5 million, or 73 cents, a year earlier. Revenue rose 32% to $254.8 million from $193.2 million. Watson attributed the loss to one-time costs and charges associated with its purchases last year of Makoff R&D Laboratories Inc. and Schein Pharmaceutical Inc.
September 20, 2000 |
Some over-the-counter calcium supplements contain small but measurable levels of lead, which over a period of years may have adverse health effects, researchers in Florida said in a study released today.
July 14, 1987 |
According to an Internal Revenue Service ruling, former shareholders of Hybritech Inc. realized $40.71 per share in March, 1986, when Eli Lilly & Co. acquired the San Diego-based biotechnology firm in a deal valued at $485 million. But the market value of the deal has mushroomed to about $90 for savvy Hybritech shareholders who picked--and held onto--the right combination of warrants, convertible notes and deferred cash payments that Lilly offered in exchange for Hybritech's common stock.